Market Overview

Mati Therapeutics Interim Phase II Nepafenac Clinical Trial Results Signal Significant Post-op Pain Reduction in Cataract Surgery Patients

Share:

Positive Trends Seen for Sustained Delivery Platform in Post-op Pain
and Inflammation

Mati
Therapeutics Inc.
("Mati") announced that it has completed a planned
interim analysis of an ongoing Phase II clinical trial evaluating the
safety and efficacy of nepafenac delivered in Mati's proprietary Evolute®
sustained ocular drug delivery platform. The trial is a multi-center,
randomized, masked evaluation of nepafenac vs. placebo in 75 patients
undergoing cataract surgery. The primary endpoint is to evaluate pain
and the secondary endpoint is to evaluate inflammation following
surgery. This planned interim analysis was conducted with approximately
50% of patients enrolled in the study.

Pain scores favored nepafenac over placebo at Day 1, Day 3, and Day 7
following surgery. At Day 3, 71% of patients treated with nepafenac
experienced No Pain versus 12% in the placebo arm. Post-operative
inflammation, as determined by cell and flare scores, also favored the
Nepafenac Evolute® arm. The treatment was generally well
tolerated with no unexpected side effects reported.

"The interim results of this ongoing Phase II trial are very
encouraging, and we are looking forward to completing the trial in the
near future," said Bob Butchofsky, CEO of Mati. "We also plan on
submitting updated study results and presenting the available data at
the upcoming American Academy of Ophthalmology meeting held in Chicago
in October. Based on these positive results we plan to initiate a larger
Phase III registration study in 2019."

"We are very encouraged by these topline results for a very promising
drug delivery platform," said Eric Donnenfeld, M.D., Ophthalmic
Consultants of Long Island and Principle Investigator of the trial. "The
ability to significantly reduce pain and inflammation while reducing or
eliminating topical medications from the most important procedure in
ophthalmology is an important achievement. Additionally, showing that
this platform can deliver an NSAID in effective, sustained therapeutic
doses is further proof that this platform can be beneficial in treating
multiple diseases within ophthalmology."

About Mati Therapeutics Inc.

Mati is developing the Evolute® sustained ocular drug
delivery platform, which Mati believes has the potential to treat a
range of ocular indications. The platform utilizes a device called a
punctal plug, which is easily inserted into a patient's punctum. The
device has already been approved to treat dry eye syndrome, but Mati is
the first to conduct clinical trials in the U.S. using punctal plugs as
an anchoring device for a drug delivery platform. A drug-eluting core is
inserted into Mati's proprietary punctal plug, which allows medication
to be continuously released into the tear film of the eye over a period
of time. Mati believes the Evolute® platform has the
potential to become a more reliable alternative to several eye drop
therapies, which can be ineffective because many patients are unwilling
or unable to adhere to self-administered eye-drop regimens.

Mati has completed multiple Phase II clinical trials using the Evolute®
platform, including multiple trials in glaucoma, ocular hypertension,
and allergy patients. Mati's proprietary punctal plug design has
demonstrated excellent lower punctum retention rates of 92% and 96% over
a 12-week follow-up period in two separate multi-center U.S. clinical
trials.

To learn more about Mati Therapeutics, visit www.MatiTherapeutics.com.

View Comments and Join the Discussion!